<table>
<thead>
<tr>
<th>Title</th>
<th>Latest version</th>
<th>Intended audience</th>
<th>Key themes</th>
<th>Document type</th>
<th>WHO website location (by topic)</th>
</tr>
</thead>
</table>
| **Continuity of essential health services: Facility assessment tool** | 12/05/2021      | National health authorities, COVID-19 incident management teams, facility managers | • Used to rapidly assess the capacity of health facilities to maintain the provision of essential health services during the COVID-19 pandemic  
  • Covers the following aspects of essential health services:  
    o Health workforce  
    o Financial management and barriers  
    o Service delivery and utilisation  
    o Infection prevention and control capacities  
    o Availability of therapeutics, diagnostics and supplies, and vaccine readiness  
    o Provision of COVID-19 primary care services                                                                                          | Interim guidance | COVID-19: Essential health services                                                 |
| **Draft landscape and tracker of COVID-19 candidate vaccines**        | 11/05/2021      | Governments, national health authorities, other stakeholders                      | • List of 99 candidate vaccines in clinical development and 184 in pre-clinical development  
  • The landscape is updated twice a week (Tuesday, Friday)  
  • Provides:  
    o summary tables of COVID-19 vaccine candidates in both clinical and pre-clinical development  
    o analysis and visualization for several COVID-19 vaccine candidate categories  
    o progress of each vaccine from pre-clinical, Phase 1, Phase 2 through to Phase 3 efficacy studies  
    o links to published reports on safety, immunogenicity and efficacy data of the vaccine candidates  
    o information on key attributes of each vaccine candidate  
  • ability to search for COVID-19 vaccines through various criteria such as vaccine platform, dosage, schedule of vaccination, route of administration, developer, trial phase and clinical endpoints being measured in Phase 3 | Publication      | R&D Blueprint                                                                    |
| **COVID-19 natural immunity**                                        | 10/05/2021      | Governments, national health authorities                                          | • Replaces previous version "Immunity passports in the context of COVID-19" (24/04/2020)  
  • Focusses on what is currently understood about SARS-CoV-2 immunity from natural infection  
  • Large cohort studies have reported that 90-99% of SARS-CoV-2 infected individuals develop neutralising antibodies within 2-4 weeks after infection  
  • How much cellular vs humoral immunity contributes to protection after natural infection is not fully understood  
  • Though rarely reported, reinfection with SARS-CoV-2 can occur  
  • Natural infection may provide similar protection against symptomatic disease as vaccination                                                                 | Scientific brief | COVID-19: Laboratory and diagnosis                                                  |
<table>
<thead>
<tr>
<th>Title</th>
<th>Latest version</th>
<th>Intended audience</th>
<th>Key themes</th>
<th>Document type</th>
<th>WHO website location (by topic)</th>
</tr>
</thead>
</table>
| Taking action on COVID-19: A toolkit for selecting and enacting change strategies that improve health worker adherence to infection prevention and control measures for COVID-19 in your health facility | 10/05/2021     | Clinicians, researchers, administrators, health professionals                    | • Describes how to use the results of a survey (see below research protocol) to select strategies that improve health care worker adherence to infection control and prevention measures for COVID-19 in the workplace  
• Divided into five parts:  
  1. The science behind connecting survey results to actionable strategies  
  2. Who should be involved?  
  3. How should we prioritise areas of focus?  
  4. Selecting recommended strategies  
  5. Enacting strategies and planning for adaptations and sustainability | Technical document | R&D Blueprint                                                                   |
| Perceptions of Healthcare Workers regarding local infection prevention control procedures for COVID-19: Research protocol | 10/05/2021     | Public health agencies, healthcare administrators, policy makers and other relevant decision makers | • Details a cross-sectional survey to evaluate perceptions of health workers’ individual and organisational preparedness to follow infection prevention and control measures in their place of work | Publication         | R&D Blueprint                    |
| Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm | 07/05/2021     | Governments, national health authorities                                          | • The COVID-19 vaccine BIBP, is an aluminium-hydroxide-adjuvanted, inactivated whole virus vaccine  
• Annexes available [here](https://www.who.int)  
• The data reviewed by WHO support the conclusion that the known benefits of the COVID-19 vaccine BIBP outweigh the risks that are known or considered possible  
• General goal and strategy for the use of BIBP vaccine against COVID-19  
• Vaccination of specific populations | Interim guidance | COVID-19: Vaccines                                                              |
| Background document on the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm | 07/05/2021     | Governments, national health authorities                                          | • Background and context  
• Characteristics of COVID-19 vaccine BIBP  
• Preclinical and clinical studies  
• Efficacy tables | Background document | COVID-19: Vaccines                                                              |
| Emergency Global Supply Chain System (COVID-19) catalogue            | 07/05/2021     | Governments, national health authorities, other stakeholders                      | • List of globally sourced COVID-19 critical supplies that are currently facing constrained market conditions  
• Supplies include personal protective equipment, diagnostics and clinical management  
• Items are available for request through the WHO COVID-19 Supply Portal, which ensures essential supplies for countries in need | Catalogue           | COVID-19: Essential resource planning                                           |
<table>
<thead>
<tr>
<th>Title</th>
<th>Latest version</th>
<th>Intended audience</th>
<th>Key themes</th>
<th>Document type</th>
<th>WHO website location (by topic)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Assessment of the Covid-19 Supply Chain System (CSCS) Summary Report</td>
<td>30/04/2021</td>
<td>Governments, national health authorities, other stakeholders</td>
<td>• In September 2020, WHO, with the advice of the CSCS Task Force (SCTF), commissioned an assessment of the Covid-19 Supply Chain System (CSCS) focused on three main areas: strategy, implementation and moving forward • This document provides a summary of the key lessons learned from 2020 and recommendations for the future. It is supported by a slide deck providing the full analysis and a summary slide deck providing an executive summary of the assessment and recommendations.</td>
<td>Report</td>
<td>Emergency Management &amp; Support</td>
</tr>
<tr>
<td>The role of health workers in the uptake of COVID-19 vaccines</td>
<td>29/04/2021</td>
<td>General public</td>
<td>• Current global situation • Role of health workers and COVID-19 vaccines o Health workers: a resource to promote COVID-19 vaccine uptake o Health worker behaviour and successful public uptake of COVID-19 vaccine • Social media listening</td>
<td>Powerpoint presentation</td>
<td>EPI-WIN updates - Update 50</td>
</tr>
<tr>
<td>Interim recommendations for use of the AZD1222 (ChAdOx1-S [recombinant]) vaccine against COVID-19 developed by Oxford University and Astra Zeneca</td>
<td>21/04/2021</td>
<td>Governments, national health authorities</td>
<td>• Updated version to reflect updated recommendations • Annexes available here • Guidance based on the evidence summarised in the background documents • General goal and strategy for the use of AZD1222 vaccine against COVID-19 • Vaccination of specific populations</td>
<td>Guidance</td>
<td>COVID-19: Critical preparedness, readiness and response</td>
</tr>
<tr>
<td>Update on Safety monitoring of COVID-19 vaccines</td>
<td>19/04/2021</td>
<td>General public</td>
<td>• Current global situation • Monitoring vaccine safety</td>
<td>Powerpoint presentation</td>
<td>EPI-WIN updates - Update 57</td>
</tr>
<tr>
<td>COVID-19 Essential supplies forecasting tool</td>
<td>14/04/2021</td>
<td>Governments, partners, other stakeholders</td>
<td>• Allows users to quantify for commodities (including PPE) used in patient and disease management • Users input infection and health care worker data for their country • Result is a detailed overview of commodity requirements and cost for the forecasted period • Commodities are predominantly hospital based, for COVID-19 patient care and diagnostic purposes</td>
<td>Excel spreadsheet tool</td>
<td>COVID-19: Essential resource planning</td>
</tr>
<tr>
<td>COVID-19 and mandatory vaccination: Ethical considerations and caveats</td>
<td>13/04/2021</td>
<td>Governments, institutional policy makers</td>
<td>• Arguments to encourage voluntary vaccination against COVID-19 should be used before contemplating mandatory vaccination • This document identifies important ethical considerations and caveats that should be explicitly evaluated and discussed through ethical analysis by governments / policy makers who may be considering mandates for COVID-19 vaccination</td>
<td>Policy brief</td>
<td>COVID-19: Vaccines</td>
</tr>
<tr>
<td>Title</td>
<td>Latest version</td>
<td>Intended audience</td>
<td>Key themes</td>
<td>Document type</td>
<td>WHO website location (by topic)</td>
</tr>
<tr>
<td>--------------------------------------------</td>
<td>----------------</td>
<td>----------------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>---------------------</td>
<td>---------------------------------</td>
</tr>
</tbody>
</table>
| Safe Ramadan practices during COVID-19     | 13/04/2021     | General public                         | • Current global situation  
• WHO guidance on holding mass gatherings  
• COVID-19 general precautionary measures  
• Precautionary measures applicable to venues  
• Stay healthy during Ramadan  
• Keep the spirit of Ramadan alive during COVID-19  
• COVID-19 vaccination during Ramadan | Powerpoint presentation | EPI-WIN updates - Update 56             |
| WHO COVID-19 guidelines and development process | 07/04/2021     | General public                         | • Current global situation  
• WHO guidelines development during COVID-19  
  o Types of guidelines  
  o Expedited development process  
  o Guidelines development group / panel  
  o Formulating a research question, evidence retrieval and establishing certainty of evidence  
  o Living guidelines | Powerpoint presentation | EPI-WIN updates - Update 55             |
| Therapeutics and COVID-19: living guideline | 31/03/2021     | Clinicians and health care decision-makers | • Updated version (31/03) contains new information and a recommendation not to use ivermectin in patients with COVID-19 except in the context of a clinical trial  
• This living guideline is driven by the urgent need for global collaboration to provide trustworthy and evolving COVID-19 guidance, informing policy and practice worldwide  
• Current practice to treat COVID-19 is variable, reflecting large scale uncertainty  
• This version makes a conditional recommendation against the use of remdesivir in hospitalised patients with COVID-19, regardless of disease severity  
• This guidance makes strong recommendations for systemic corticosteroids in patients with severe and critical COVID-19, and a conditional recommendation against systemic corticosteroids in patients with non-severe COVID-19 | Living guidance | COVID-19: Clinical care |
| Clinical long-term effects of COVID-19     | 26/03/2021     | General public                         | • Current global situation  
• Long-term effects of COVID-19  
  o Clinical course  
  o Lingering and reported symptoms after infection  
  o Risk of long-term health problems  
  o Long-term effects of other coronaviruses | Powerpoint presentation | EPI-WIN updates - Update 54             |
<table>
<thead>
<tr>
<th>Title</th>
<th>Latest version</th>
<th>Intended audience</th>
<th>Key themes</th>
<th>Document type</th>
<th>WHO website location (by topic)</th>
</tr>
</thead>
</table>
| COVID-19 vaccination and travel                                       | 19/03/2021     | General public                         | • Current global situation  
• World wide travel measures in place  
• Temporary recommendation – WHO does not recommend requirements of proof of vaccination for travel  
• Scientific, ethical, legal and technological considerations around proof of vaccination and international travel  
• Proposed framework for digital vaccination certificates  
• Risk assessment for SARS-CoV-2 testing in the context of international travel  
• Webinar recording                                                                 | Powerpoint presentation | EPI-WIN updates - Update 53                  |
| Background document to the WHO Interim recommendations for use of Ad26.COV2.S (COVID-19) vaccine | 17/03/2021     | Governments, national health authorities | • Background and context  
• Characteristics of Ad26.COV2.S (COVID-19) vaccine  
• Preclinical and clinical studies  
• Efficacy tables                                                                 | Background document | COVID-19: Vaccines                        |
| Interim recommendations for the use of the Janssen Ad26.COV2.S (COVID-19) vaccine | 17/03/2021     | Governments, national health authorities | • Guidance based on the evidence summarised in the background documents  
• General goal and strategy for the use of the Janssen Ad26.COV2.S (COVID-19) vaccine  
• Vaccination of specific populations  
• Recommendations on addressing current knowledge gaps through further research                                                                 | Guidance | COVID-19: Vaccines                        |
| COVID-19 vaccines and immune response                                | 11/03/2021     | General public                         | • Current global situation  
• The immune response  
• Vaccine development  
• Vaccine results  
• Webinar recording                                                                 | Powerpoint presentation | EPI-WIN updates - Update 52                 |
| Pandemic overview, where are we now?                                 | 04/03/2021     | General public                         | • Current global situation and overview of the COVID-19 pandemic  
  o Stage 1 – an unknown virus emerges  
  o Stage 2 – a pandemic unfolds  
  o Stage 3 – the pandemic accelerates  
  o Stage 4 – a multifaceted pandemic  
  o Stage 5 – medical countermeasures                                                                 | Powerpoint presentation | EPI-WIN updates - Update 51                 |
| WHO Living guideline: Drugs to prevent COVID-19                      | 02/03/2021     | Clinicians, health care decision-makers | • Contains new information and a recommendation on hydroxychloroquine  
• Makes a strong recommendation against the use of hydroxychloroquine prophylaxis for individuals who do not have COVID-19  
• This is a living guideline, so the recommendation will be updated, and new recommendations will be added on other prophylactic interventions for COVID-19                                                                 | Guidance | COVID-19: Infection prevention and control / WASH |
<table>
<thead>
<tr>
<th>Title</th>
<th>Latest version</th>
<th>Intended audience</th>
<th>Key themes</th>
<th>Document type</th>
<th>WHO website location (by topic)</th>
</tr>
</thead>
</table>
| Roadmap to improve and ensure good indoor ventilation in the context of COVID-19 | 01/03/2021     | Health care facility managers, building managers, general public | • Aims to define the key questions users should consider to assess indoor ventilation and the major steps needed to reach recommended ventilation levels or improve air quality to reduce the risk of spread of COVID-19  
• Includes recommendations on how to assess and measure the different parameters, specifically in health care, non-residential and residential settings whenever a person is under home care or home quarantine | Roadmap         | COVID-19: Infection prevention and control / WASH               |
| ChAdOx1-S [recombinant] COVID-19 vaccine                              | 26/02/2021     | Governments, national health authorities, other stakeholders | • COVID-19 Vaccine Explainer for the ChAdOx1-S [recombinant] vaccine developed by Oxford University and AstraZeneca  
• Data reviewed at this time supports the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks  
• Describes the following:  
  o Product characteristics  
  o Schedule and administration  
  o Stability and storage  
  o Labelling and packaging  
  o Safety information | Vaccine Explainer | COVID-19: Vaccines                                       |
| 10 steps to community readiness                                       | 22/02/2021     | General public                                        | • Step by step guidance to prepare communities for a COVID-19 vaccine, treatment or a new test  
• Current global situation | Powerpoint presentation | EPI-WIN updates - Update 50                                |
| Maintaining a safe and adequate blood supply and collecting convalescent plasma in the context of the COVID-19 pandemic | 17/02/2021     | Blood services, national health authorities, and others responsible for the provision of blood | • Update to previous version (10/07/2020)  
• Guidance on management of blood supply in COVID-19 pandemic  
• Outlines actions and measures to:  
  omitigate risk of transmission through transfusion of blood and blood products  
  omitigate risk of staff and donor exposure  
  omitigate impact of reduced availability of donors  
  omanage demand for blood and blood products  
  oensures undisrupted supplies of critical material and equipment  
  omaintain communication  
  ocollect COVID-19 convalescent plasma  
• Updated version provides additional information on:  
  o Recommendations for donors who have received a vaccine against SARS-CoV-2  
  oReported experience with experimental use of convalescent plasma  
  oNewly established reagent for normalisation of assays for binding and neutralising activity of antibodies to SARS-CoV-2 | Guidance        | COVID-19: Clinical care                                    |
<table>
<thead>
<tr>
<th>Title</th>
<th>Latest version</th>
<th>Intended audience</th>
<th>Key themes</th>
<th>Document type</th>
<th>WHO website location (by topic)</th>
</tr>
</thead>
</table>
| Immune response to SARS-CoV-2 & viral infections | 12/02/2021 | General public | • Current global situation  
• Immune response to viral infections  
• Innate immune response  
• Adaptive immune response – T cells and B cells  
• Re-infection of SARS-CoV-2  
• SARS-CoV-2 variants and COVID-19 vaccines | Powerpoint presentation | EPI-WIN updates - Update 49 |
| AZD1222 vaccine against COVID-19 developed by Oxford University and Astra Zeneca: Background paper (draft) | 10/02/2021 | Governments, national health authorities | • Provides background evidence related to the interim recommendations for use of the AZD1222 (ChAdOx1-S [recombinant]) vaccine against COVID-19 developed by Oxford University and Astra Zeneca  
• Characteristics of AZD1222 vaccine against COVID-19 | Background paper | COVID-19: Critical preparedness, readiness and response |
| Definition and categorisation of the timing of mother-to-child transmission of SARS-CoV-2 | 08/02/2021 | Obstetricians, neonatologists, paediatricians, national health authorities | • Presents evidence based on rapid reviews of literature and results of a living systematic review on pregnancy and COVID-19, on:  
  o Potential mechanisms of vertical transmission  
  o Feasibility of vertical transmission of SARS-CoV-2  
  o Data related to interpretation of positive SARS-CoV-2 viologic and serologic neonatal tests  
  o Lessons from diagnosis of other congenital infections  
  o Existing proposed definitions to classify timing of vertical transmission of SARS-CoV-2  
• Concluded that at this time there is limited evidence on the extent of SARS-CoV-2 vertical transmission and its timing | Scientific brief | COVID-19: Scientific briefs |
| An update on the allocation of COVID-19 vaccines | 07/02/2021 | General public | • Global access to COVID-19 vaccines  
• COVAX facility  
• Global COVID-19 vaccine allocation  
• Allocation of vaccines within individual countries  
• Humanitarian buffer of up to 5% of total number of vaccines supplied by COVAX, reserved for vulnerable populations | Powerpoint presentation | EPI-WIN updates - Update 48 |
| Community needs, perceptions and demand: community assessment tool | 05/02/2021 | National and subnational health authorities, COVID-19 incident management teams, facility managers | • Can be used by countries to rapidly assess and respond to community health needs and perceptions around access and effective use of essential health services during the COVID-19 outbreak  
• Covers the following aspects:  
  o Unmet needs for essential health services  
  o perceived barriers to use of essential health services, considering both supply and demand factors;  
  o attitudes towards COVID-19 vaccination;  
  o community assets and vulnerabilities; and  
  o barriers to the provision of community-based services. | Guidance | COVID-19: Essential health services |
<table>
<thead>
<tr>
<th>Title</th>
<th>Latest version</th>
<th>Intended audience</th>
<th>Key themes</th>
<th>Document type</th>
<th>WHO website location (by topic)</th>
</tr>
</thead>
</table>
| Background document on the mRNA-1273 vaccine (Moderna)     | 03/02/2021     | Governments and national health authorities                | • Background document to the WHO interim recommendations for use of the mRNA-1273 vaccine (Moderna)  
  • Characteristics of COVID-19 vaccine mRNA-1273 (Moderna)  
  • Efficacy of the Moderna mRNA-1273 COVID-19 vaccine  
  • Safety of the Moderna mRNA-1273 COVID-19 vaccine       | Background document | COVID-19: Critical preparedness, readiness and response     |
| COVID-19: Occupational health and safety for health workers| 02/02/2021     | Employers and health-facility managers, health workers and their representatives, OHS experts, infection prevention and control experts, policy makers at national and subnational levels | • Update of previous version (18/03/2020)  
  • Provides specific measures to protect occupational health and safety of health workers and highlights the duties, rights and responsibilities for health and safety at work in the context of COVID-19  
  • Updated version contains additional information on:  
  o Conducting workplace risk assessments  
  o Hierarchy of hazard controls to prevent infection  
  o Prolonged use of PPE  
  o Use of disinfectants  
  o Workload, work time and work organisation – including recommendations for prevention of fatigue during an emergency situation  
  o Violence, harassment, discrimination and stigma  
  o Mental health and psychosocial support  
  o Sanitation, hygiene and rest facilities  
  o Occupational health services | Guidance | COVID-19: Schools, business and institutions |
| Contact tracing in the context of COVID-19                 | 01/02/2021     | Governments and national health authorities                | • Update of previous version (10/05/2020)  
  • Updated topics include:  
  o lessons learned on contact definition  
  o community engagement operational principles in the context of contact tracing  
  o digital tools for contact tracing, and examples of key performance indicators (KPIs).  
  • Provides guidance on how to establish contact tracing capacity for the control of COVID-19, and how to prioritise contact tracing activities in different settings | Guidance | COVID-19: Surveillance, case investigation and epidemiological protocols |
| SARS-CoV-2 virus mutations and variants                    | 29/01/2021     | General public                                             | • Current global situation  
  • How viruses change over time  
  • New emerging SARS-CoV-2 variants  
  • SARS-CoV-2 variant emerged among mink in Denmark  
  • The variant detected in the United Kingdom  
  • Another variant emerges in South Africa  
  • Implications of variants detected in the UK and South Africa  
  • Increased transmissibility of variants detected in the UK and South Africa  
  • Monitoring of SARS-CoV-2 variants  
  • Global response to the emergence of new variants  
  • Communicating with the public about SARS-CoV-2 variants | Powerpoint presentation | EPI-WIN updates - Update 47 |
<table>
<thead>
<tr>
<th>Title</th>
<th>Latest version</th>
<th>Intended audience</th>
<th>Key themes</th>
<th>Document type</th>
<th>WHO website location (by topic)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laboratory biosafety guidance related to coronavirus disease 2019 (COVID-19)</td>
<td>28/01/2021</td>
<td>Laboratories and stakeholders involved in COVID-19 virus laboratory work</td>
<td>• Update of previous version (13/05/2020)</td>
<td>Guidance</td>
<td>COVID-19: Laboratory and diagnosis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• The following topics have been added:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>o biosafety aspects for working with antigen-detecting rapid diagnostic tests</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>o handling new variants of SARS-CoV-2 in the laboratory</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>o updated assay decontamination before disposal</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>o personal protective equipment (PPE) for specimen collection</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>o chemical hazards and their safe disposal</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Guidance for laboratories and stakeholders involved in COVID-19 virus laboratory work</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Includes packing and shipment of specimens for COVID-19 confirmatory testing</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Recommendations addressing minimal/essential working conditions associated with specific manipulations in laboratory settings</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interim recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19</td>
<td>25/01/2021</td>
<td>Clinicians and health care decision-makers</td>
<td>• Developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunisation (SAGE)</td>
<td>Guidance</td>
<td>COVID-19: Critical preparedness, readiness and response</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Based on evidence summarised in the background document on mRNA vaccine (Moderna) against COVID-19 and the background paper on COVID-19 diseases and vaccines</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Outlines goal and strategy for use of the Moderna mRNA-1273 vaccine against COVID-19, including:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>o Vaccination of specific populations</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>o Special settings</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>o Other considerations</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Contains five new recommendations and a new chapter on care for patients after acute illness with COVID-19</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Describes key actions that should be taken to enable delivery of clinical and public health services across different scenarios:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>o No cases</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>o Sporadic cases</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>o Clusters of cases</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>o Community transmission</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Title</td>
<td>Latest version</td>
<td>Intended audience</td>
<td>Key themes</td>
<td>Document type</td>
<td>WHO website location (by topic)</td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>----------------</td>
<td>-----------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>---------------------</td>
<td>---------------------------------</td>
</tr>
</tbody>
</table>
| Online global consultation on contact tracing for COVID-19, 9-11 June 2020 | 22/01/2021     | Governments and national health authorities                                      | • The report captures the meeting deliberations and key recommendations of WHO and GOARNs COVID-19 contact tracing response.  
• Includes:  
  o Lessons learned;  
  o Known and emerging best practices;  
  o Measures necessary for urgent implementation, scale-up, maintenance & enhancement for contact tracing activities;  
  o Addresses ways to strengthen the contact tracing response;  
  o Reviews operational experiences together to further improve collaboration and coordination between partners. | Publication         | WHO HQ                          |
| Testing strategies for COVID-19                                      | 15/01/2021     | General public                                                                    | • The latest on the COVID-19 global situation and how to use testing to achieve public health goals  
• Provides an overview of:  
  o How to use testing to achieve public health goals  
  o COVID-19 testing  
  o Isolate and treat cases  
  o Public health considerations  
  o Outbreaks and clusters  
  o COVID-19 protection measures | Powerpoint presentation | EPI-WIN updates - Update 46                                      |
| Aide-memoire: Infection prevention and control (IPC) principles and procedures for COVID-19 vaccination activities | 15/01/2021     | Policy makers, immunisation programme managers, infection prevention and control focal points, health works involved in COVID-19 vaccination delivery | • Summarises the key infection control and prevention principles to consider and the precautions to take for safely delivering COVID-19 vaccines  
• Based on WHO infection prevention and control and immunisation standards and other guidance in the context of COVID-19 | Aide-memoire        | COVID-19: Infection prevention and control / WASH |
| Analysing and using routine data to monitor effects of COVID-19 on essential health services; practical guide for national and subnational decision-makers | 14/01/2021     | Managers of health services at national and subnational levels, other essential health services | • Can be used to help countries monitor and analyse the impact of COVID-19 on essential health services to inform planning and decision-making  
• Provides recommendations on:  
  o How to use KPI’s to analyse changes in access to and develop of essential health services  
  o How to visualise and interpret these data  
  o How to use findings to guide modifications for safe delivery of services and transitioning towards restoration and recovery | Guidance            | COVID-19: Essential health services |
<table>
<thead>
<tr>
<th>Title</th>
<th>Latest version</th>
<th>Intended audience</th>
<th>Key themes</th>
<th>Document type</th>
<th>WHO website location (by topic)</th>
</tr>
</thead>
</table>
| Interim recommendations for the use of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing | 08/01/2021     | Governments and national health authorities | • Advice issued by the Strategic Advisory Group of Experts on Immunisation (SAGE) meeting held on 5th January 2021  
• The known and potential benefits of BNT162b2 outweigh the known and potential risks  
• Countries are recommended to use the WHO Prioritization Roadmap and the WHO Values Framework as guidance for their prioritization of target groups  
• In settings with community transmission, the Roadmap recommends that priority be given initially to health workers at high risk and older people with and without comorbidities | Guidance      | Strategic Advisory Group of Experts on Immunisation (SAGE) |
| Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health | 08/01/2021     | Laboratories                              | • Recent advances have allowed the genomes of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the causative agent of COVID-19 – to be sequenced within hours or days of a case being identified. As a result, for the first time, genomic sequencing in real time has been able to inform the public health response to a pandemic  
• This document provides guidance for laboratories on maximizing the impact of SARS-CoV-2 sequencing activities now and in the future  
• Provides information on the considerations to be taken into account when planning or conducting a SARS-CoV-2 sequencing programme, to ensure that best use is made of the results in improving public health  
• Raises practical questions, details the possible applications and limitations of genomic analyses, and provides brief guidance on technical strategies for sequencing and analysis. | Implementation guide | COVID-19: Laboratory and diagnosis |
| SARS-CoV-2 genomic sequencing for public health goals                | 08/01/2021     | Policy makers and stakeholders             | • Guidance on how to maximise the public health benefit of SARS-CoV-2 genomic sequencing activities in the short and long term  
• Practical considerations for the implementation of a virus genomic sequencing program and an overview of the public health objectives of the genomic sequencing are covered  
• Recommended that countries wishing to build sequencing capacity for SARS-CoV-2 do so as part of a broader plan to build capacity to detect and monitor other pathogens of public health concern | Guidance      | COVID-19: Laboratory and diagnosis |
<table>
<thead>
<tr>
<th>Title</th>
<th>Latest version</th>
<th>Intended audience</th>
<th>Key themes</th>
<th>Document type</th>
<th>WHO website location (by topic)</th>
</tr>
</thead>
</table>
| Infection prevention and control guidance for long-term care facilities in the context of COVID-19 update | 08/01/2021     | Long term care facility managers and corresponding focal persons in long term care facilities | Contains updated results from published studies on epidemiology, effectiveness of infection prevention and control precautions, and impact of these precautions on the mental and physical health and wellbeing of older people  
Contains updated advice on:  
o  infection prevention and control precautions to prevent spread and protect health workers and caregivers of patients with suspected of confirmed COVID-19  
o  early detection of and testing for SARS-CoV-2 among residents and staff  
o  policies for visitors to long term care facilities and additional considerations on minimising the mental and physical health impacts of restrictions and precautions  
Provides guidance on infection prevention and control in long term care facilities in the context of COVID-19 in order to:  
o  Prevent COVID-19 virus from entering the facility  
o  Prevent COVID-19 from spreading within the facility  
o  Prevent COVID-19 from spreading to outside the facility  
System and service coordination to provide long-term care  
Prevention, response and reporting  
Minimising the effect of infection prevention and control on the mental health of residents, employees and visitors | Guidance       | COVID-19: Infection prevention and control / WASH                                   |
| Novel Coronavirus: Human-animal-environment interface research       | 08/01/2021     | Governments, national health authorities, research laboratories                    | A global research roadmap to accelerate research that can contribute to containing the spread of this epidemic and to facilitate that those affected receive optimal care  
The research priorities identified at the Human-Animal-Environment Interface are listed in the document and include:  
o  Investigation of possible animal host ranges (including wildlife, farmed wildlife, livestock, companion animals, stray animals, pests/vermin), investigation of the potential transmission pathways between susceptible animal(s) and to humans and vice versa  
o  Confirmation of the role of candidate species through virus persistence, amplification and excretion studies. Continued assessment of the role of known susceptible hosts in amplifying and maintaining the virus  
o  Studies on candidate animal-human interactions, including the persistence of the virus in the environment of this interface. Continued investigation of viral persistence under a variety of environmental conditions including food processing, packing and shipment modalities. | Technical document | R&D Blueprint                     |
<table>
<thead>
<tr>
<th>Title</th>
<th>Latest version</th>
<th>Intended audience</th>
<th>Key themes</th>
<th>Document type</th>
<th>WHO website location (by topic)</th>
</tr>
</thead>
</table>
| Update on COVID-19 vaccine development                                | 21/12/2020     | General public                                                | • The latest on the COVID-19 global situation and vaccine development  
  o Current global situation  
  o Vaccines – about vaccines, vaccine development, WHO vaccine and immunisation-related commitments  
  o WHO guidance and resources  
  o How to protect ourselves and others | PowerPoint presentation                              | EPI-WIN updates – Update 45                                          |
| WHO recommendation COVID-19 mRNA vaccine (nucleoside modified) - COMIRNATY® | 31/12/2020     | Governments, national health authorities, other stakeholders | • On 31 Dec, WHO listed the Comirnaty COVID-19 mRNA vaccine for emergency use  
  • Based on the available evidence assessed, WHO found sufficient data is available on the Comirnaty, COVID-19 mRNA vaccine (nucleoside modified) for an Emergency Use Listing (EUL) recommendation  
  • This supports countries to expedite their own regulatory approval processes to import and administer the vaccine and enables UNICEF and the Pan-American Health Organization to procure the vaccine for distribution to countries in need  
  • Comirnaty, COVID-19 mRNA vaccine (nucleoside modified) is a vaccine for preventing coronavirus disease 2019 (COVID-19) in individuals aged 16 years and older  
  • The vaccine requires storage using an ultra-cold chain; it needs to be stored at -60°C to -90°C degrees | Recommendation and product sheet | WHO - Prequalification of Medical Products (IVDs, Medicines, Vaccines and Immunization Devices, Vector Control) |
| Statement of the WHO Working Group on COVID-19 Animal Models (WHO-COM) about the UK and South African SARS-CoV-2 new variants | 23/12/2020     | Governments, national health authorities, other stakeholders | • Statement summarising WHO-COM meeting on 22 December 2020 to discuss current knowledge and action plans about the emerging SARS-CoV-2 variants that are currently circulating in the UK and South Africa.  
  • Epidemiological data suggests that these two variants may be associated with increased transmissibility. | Meeting Report               | R&D Blue Print                                                      |
| Rational use of personal protective equipment for coronavirus disease (COVID-19) and considerations during severe shortages | 23/12/2020     | Those involved in distribution and management of PPE, public health authorities, individuals in health care and community settings | • Recommendations for use of PPE in healthcare and home care settings, as well as during the handling of cargo from affected countries  
  • Assesses current disruption of the global supply chain  
  • Considerations for decision making during severe PPE shortages  
  • Recommendations for optimising the availability of PPE | Interim Guidance           | COVID-19: Infection prevention and control / WASH                    |
<p>| Evidence to recommendations: Methods used for assessing health equity and human rights considerations in COVID-19 and aviation | 23/12/2020     | Member states, general public, aviation industry             | • Describes the process that WHO will undertake to assess the reporting of key factors related to health equity and human rights in the primary literature of specific public health interventions as they relate to COVID-19 and aviation. | Interim Guidance           | COVID-19: Travel, Points of Entry and Border Health                  |</p>
<table>
<thead>
<tr>
<th>Title</th>
<th>Latest version</th>
<th>Intended audience</th>
<th>Key themes</th>
<th>Document type</th>
<th>WHO website location (by topic)</th>
</tr>
</thead>
</table>
• The updated strategy builds on the learnings from the response to-date. The shift presented in the document is towards the community engagement and participatory approaches that have been proven to help control and eliminate outbreaks in the past.  
• OVERARCHING GOAL: That people-centred and community-led approaches are championed widely – resulting in increased trust and social cohesion, and ultimately a reduction in the negative impacts of COVID-19. | Interim Guidance | Risk Communication and community engagement                                       |
| Background paper on Covid-19 disease and vaccines                    | 22/12/2020     | Governments, national health authorities, other stakeholders                      | • Draft background paper on COVID-19 disease and vaccines prepared by the SAGE working group                                                                                                                  | Technical Document | Immunization, Vaccines and Biologicals, Strategic Advisory Group of Experts on Immunization |
| SARS-CoV-2 antigen-detecting rapid diagnostic tests: An implementation guide | 21/12/2020     | COVID-19: Laboratory and diagnosis; Ministries of Health, donors, public & private organizations/agencies testing for SARS-CoV2 | • Provides an overview of the major elements that must be considered before, during and after the implementation of antigen-detecting rapid diagnostic tests (Ag-RDTs) for SARS-CoV-2. This guide is complementary to policy guidance issued by the World Health Organization (WHO).  
• The guide may appeal to a range of audiences including Ministries of Health, donors, public and private organizations/agencies acting as implementing partners and community based and civil society organizations with experience working on health, especially organizations familiar with similar testing campaigns for other disease programmes like HIV and malaria | Implementation Guide | Disease Control in Humanitarian Emergencies, Emergencies Preparedness |
| Emergency use designation of COVID-19 candidate vaccines: ethical considerations for current and future COVID-19 placebo-controlled vaccine trials and trial unblinding | 18/12/2020     | Researchers, sponsors, regulators, research ethics committees, policy-makers        | • Considerations for the conduct of COVID-19 vaccine trials in the context of a candidate vaccine being granted emergency use designation  
• Position of existing global research ethics guidance documents on placebo use  
• Ethics of continuing the conduct of blinded, placebo-control COVID-19 vaccine trials in the context of a candidate vaccine being issued with EUD and being publicly accessible | Policy brief     | COVID-19: Critical preparedness, readiness and response                           |
<table>
<thead>
<tr>
<th>Title</th>
<th>Latest version</th>
<th>Intended audience</th>
<th>Key themes</th>
<th>Document type</th>
<th>WHO website location (by topic)</th>
</tr>
</thead>
</table>
| COVID-19 diagnostic testing in the context of international travel   | 16/12/2020     | National authorities, decision makers                  | • A thorough risk assessment should be a key element of the decision-making process regarding SARS-CoV-2 testing policies for international travellers  
  • Includes the following:  
    o Reliability of testing before or after travel  
    o Potential impact of testing international travellers on national priority testing capacity  
    o Costs associated with testing international travellers  
    o Available options for SARS-CoV-2 testing  
    o Operational challenges of implementing testing requirements | Scientific brief | COVID-19: Scientific briefs                           |
| Risk assessment tool to inform mitigation measures for international travel in the context of COVID-19 | 16/12/2020     | National authorities, decision makers                  | • Provides detailed guidance on how to implement risk mitigation measures for the gradual resumption of international travel by conducting a risk assessment using a mixed-methods approach  
  • This risk assessment methodology is most useful for destination countries experiencing community transmission | Annex         | COVID-19: Travel, points of entry and border health   |
| Considerations for implementing a risk-based approach to international travel in the context of COVID-19 | 16/12/2020     | National authorities, decision makers                  | • During the pandemic, international travel should be prioritised for emergencies and humanitarian actions, travel of essential personnel, repatriations, and cargo transport for essential supplies  
  • Countries should introduce risk mitigation measures to prevent transmission of SARS-CoV-2 as they begin to resume international travel  
  • Risk assessments can be conducted using a mixed-methods approach, as described in this document  
  • WHO does not recommend international travellers as a priority group for testing, nor does WHO recommend the use of “immunity certificates” for international travel | Guidance       | COVID-19: Travel, points of entry and border health   |
<p>| Supplement to WHO Vaccine Position Papers                            | 15/12/2020     | Member states, Countries and regions developing COVID-19 vaccine recommendations, | • Supplementary document describing vaccine guideline development group Strategic Advisory Group of Experts (SAGE) on Immunization. | Guidance       | COVID19: Overview                                    |
| CORRIGENDA - Evidence to recommendations: COVID-19 mitigation in the aviation sector | 15/12/2020     | Member states, general public, aviation industry     | • Describes the process WHO will undertake to synthesize the available data on the effectiveness, safety, and potential harms of various public health mitigation measures for SARS-CoV-2 transmission implemented before, during, and after air travel, including at points of entry. | Guidance       | COVID-19: Travel, points of entry, and border health |</p>
<table>
<thead>
<tr>
<th>Title</th>
<th>Latest version</th>
<th>Intended audience</th>
<th>Key themes</th>
<th>Document type</th>
<th>WHO website location (by topic)</th>
</tr>
</thead>
</table>
| 24th WHO Regulatory Update on COVID-19                              | 11/12/2020     | National regulatory authorities, regulatory networks and associated stakeholders  | • Summarises regulatory updates on COVID-19 based on:  
  o Highlights & main issues  
  o Update on ACT-Accelerator  
  o In Vitro diagnostics  
  o Therapeutics  
  o Vaccines  
  o Research protocols, assays & reference standards  
  o Substandard & falsified products  
  o Supply chain  
  o Medical devices                                                      | Guidance                | COVID-19: Scientific briefs                                                      |
| Checklist to support schools re-opening and preparation for COVID-19 resurgences or similar public health crises | 11/12/2020     | Policy makers, staff and officials from education and health sectors, parents and caregivers | • Checklist to enhance compliance and adherence with the public health measures outlined in “Considers for school-related public health measures in the context of COVID-19”, particularly taking into consideration children under the age of 18 years in educational settings and schools with limited resources  
  • Structured around protective measures related to:  
    o Hand hygiene and respiratory etiquette  
    o Physical distancing  
    o Use of masks in schools  
    o Environmental cleaning and ventilation  
    o Respecting procedures for isolation of all people with symptoms | Checklist                | COVID-19: Schools, businesses and institutions                                  |
| Public health considerations for elections and related activities in the context of the COVID-19 pandemic | 10/12/2020     | National and local health authorities                                              | • Provides details on the approach that should be followed to decrease the risk of transmission of SARS-CoV-2 during in-person events related to elections and associated activities  
  • Includes the following:  
    o General advice  
    o Precautionary measures related to venues  
    o Personal protective equipment  
    o Precautionary measures related to special population groups | Guidance                | COVID-19: Mass gatherings                                                       |
| How to select, implement and adjust public health and social measures | 09/12/2020     | General public                                                                     | • Update on the global situation  
  • Considerations for implementing and adjusting public health and social measures  
    o Assess level of transmission  
    o Assess health system response capacity  
    o Assign situational level  
    o Select measures  
    o Communicate measures  
    o Implement and adjust measures | Powerpoint presentation | EPI-WIN updates – Update 44                                                      |
<table>
<thead>
<tr>
<th>Title</th>
<th>Latest version</th>
<th>Intended audience</th>
<th>Key themes</th>
<th>Document type</th>
<th>WHO website location (by topic)</th>
</tr>
</thead>
</table>
| Health workforce policy and management in the context of the COVID-19 pandemic response | 03/12/2020 | Health managers, policymakers | • Consolidates COVID-19 guidance for the design, management and preservation of the workforce necessary to manage the COVID-19 pandemic and maintain essential health services  
• Identifies recommendations at individual, management, organisational and system levels  
• Covers the following domains:  
  o Supporting and protecting health workers  
  o Strengthening and optimizing health workforce teams  
  o Increasing capacity and strategic health worker deployment  
  o Health system human resources strengthening | Guidance | COVID-19: Essential health services |
| Ending the COVID-19 pandemic: The need for a global approach | 03/12/2020 | Member states | • Analysis suggests that leaving low and lower middle income countries to fend for themselves amid the COVID-19 pandemic will cause significant economic damage that puts decades of economic progress at risk  
• The Access to COVID-19 Tools (ACT) Accelerator program is the only end-to-end complete global solution – across tests, treatments and vaccines – for tackling the pandemic  
• This analysis suggests that the economic benefits of an equitable vaccine solution accrued by ten countries (US, UK, Germany, Japan, France, Canada, Qatar, South Korea, Sweden, UAE) would be at least $153 billion in 2020-21  
• Apart from the clear economic benefits, each country involved stands to gain geopolitically | Publication | ACT-Accelerator |
| Technical Brief: Regulation of COVID-19 vaccines, Synopsis from the COVAX RAG meetings | 03/12/2020 | Vaccine developers, regulatory authorities | • Promotes regulatory preparedness among COVID-19 vaccine developers  
• Informs wider community of Regulatory Authorities of questions and challenges vaccine developers are facing  
• The Regulatory Advisory Group (RAG) has members from Argentina, Australia, Brazil, Canada, Europe, Ghana, Japan, Singapore and USA | Annex to Regulatory update | COVID-19: Scientific briefs |
<p>| Feasibility, potential value and limitations of establishing a closely monitored challenge model of experimental COVID-19 infection and illness in healthy young adult volunteers | 02/12/2020 | Health authorities | • Final report on the WHO Advisory Group tasked to consider the feasibility, potential value and limitations of establishing a closely monitored challenge model of experimental COVID-19 infection and illness in healthy young adult volunteers | Technical document | |</p>
<table>
<thead>
<tr>
<th>Title</th>
<th>Latest version</th>
<th>Intended audience</th>
<th>Key themes</th>
<th>Document type</th>
<th>WHO website location (by topic)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advice on the use of masks in the context of COVID-19</td>
<td>01/12/2020</td>
<td>Decision makers, public health and IPC professionals, health care managers, health workers</td>
<td>• Contains scientific evidence relevant to the use of masks for preventing transmission of COVID-19, as well as practical considerations&lt;br&gt;• Guidance on use of masks in health care settings&lt;br&gt;  o Use of medical masks and respirators to provide care to suspected or confirmed COVID-19 patients&lt;br&gt;  o Continuous medical mask use by health workers in areas of community transmission&lt;br&gt;  o Types of masks for use by health care works depending on transmission scenario, setting and activity&lt;br&gt;  o Alternatives to medical masks in health facilities&lt;br&gt;  o Additional considerations for community care settings&lt;br&gt;• Guidance on the use of masks for general public&lt;br&gt;  o Examples of where general public should use masks in areas with known or suspected community transmission&lt;br&gt;  o Types of masks to consider&lt;br&gt;  o Non-medical mask filtration efficiency, pressure drop and filter quality factor&lt;br&gt;  o Summary guidance and practical considerations for non-medical masks production and management&lt;br&gt;• Guidance on the use of medical masks for the care of COVID-19 patients at home&lt;br&gt; • Guidance on mask management</td>
<td>Guidance</td>
<td>COVID-19: Infection prevention and control / WASH</td>
</tr>
<tr>
<td>COVID-19 Therapeutics Target Product Profile for Hospitalised Patients</td>
<td>30/11/2020</td>
<td>All those working to evaluate repurposed therapeutic agents for COVID-19, or to develop new therapeutic agents for COVID-19</td>
<td>• Describes the preferred and minimally acceptable profiles for therapeutic agents&lt;br&gt; • Intended to guide and prioritise the evaluation of repurposed therapeutic agents for COVID-19 or the development of new therapeutic agents&lt;br&gt; • Details the Target Product Profiles for symptomatic mild cases, hospitalised moderate to severe cases, and hospitalised critical cases</td>
<td>Publication</td>
<td>R&amp;D Blueprint</td>
</tr>
<tr>
<td>Infodemic management and the COVID-19 pandemic</td>
<td>29/11/2020</td>
<td>General public</td>
<td>• Update on the global situation&lt;br&gt; • Infodemic management&lt;br&gt;  o An infodemic is accompanying the pandemic&lt;br&gt;  o The COVID-19 infodemic can harm health&lt;br&gt;  o Technology has changed the way information is produced, distributed and consumed&lt;br&gt;  o How people receive, process and act on information varies&lt;br&gt;  o How to manage the infodemic - the right information at the right time in the right format&lt;br&gt;  o Quantifying information through social listening&lt;br&gt;  o Promoting resilience to misinformation</td>
<td>Powerpoint presentation</td>
<td>EPI-WIN updates – Update 43</td>
</tr>
<tr>
<td>Title</td>
<td>Latest version</td>
<td>Intended audience</td>
<td>Key themes</td>
<td>Document type</td>
<td>WHO website location (by topic)</td>
</tr>
<tr>
<td>-----------------------------------------------------------------</td>
<td>----------------</td>
<td>-----------------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>---------------</td>
<td>---------------------------------</td>
</tr>
</tbody>
</table>
| Rapid hospital readiness checklist                              | 26/11/2020     | Hospital managers, national and subnational health authorities, incident management teams, facility managers | • Countries can use this checklist of hospital governance, structures, plans and protocols to rapidly determine the current capacities of hospitals to respond to the COVID-19 pandemic and to identify gaps and major areas that require investment and action for the development of hospital readiness improvement plans  
• The tool can be used periodically to monitor hospital emergency operational readiness capacity development | Interim guidance | COVID-19: Essential health services                                           |
| Considerations for the Assessment of COVID-19 Vaccines for Listing by WHO | 25/11/2020     | Manufacturers of COVID-19 vaccines                                                 | • Provides advice to manufacturers on the process and criteria that will be used by WHO to evaluate COVID-19 vaccines that are submitted either for prequalification or Emergency Use Listing.  
• The following is described:  
  o Submission and review processes  
  o Criteria that will be used to assess clinical trial design, endpoints and statistical criteria  
  o Specific data that should be submitted to answer questions  
  o Manufacturing, quality control and labelling requirements  
  o Non-clinical data to address the potential for vaccine-associated enhanced disease  
  o Post-authorisation commitments | Guidance       | COVID-19: Laboratory and diagnosis                                              |
| COVID-19 and mink                                               | 23/11/2020     | General public                                                                    | • Update on the global situation  
• Mink and SARS-CoV-2  
  o SARS-CoV-2 in farmed mink  
  o Mink SARS-CoV-2 in people: Denmark  
  o Cluster 5 variant and implications for vaccine development  
  o Reducing the risk of transmission of SARS-CoV-2 between humans and farmed animals | Powerpoint presentation | EPI-WIN updates – Update 42                                                      |
• Designed to help identify health system bottlenecks in order to monitor and track the continuity of essential health services.  
• Can be used by countries to rapidly assess the capacity of health facilities to maintain the provision of essential health services during the COVID-19 pandemic. | Guidance       | COVID-19: Essential health services                                           |
<table>
<thead>
<tr>
<th>Title</th>
<th>Latest version</th>
<th>Intended audience</th>
<th>Key themes</th>
<th>Document type</th>
<th>WHO website location (by topic)</th>
</tr>
</thead>
</table>
| Diagnostics, therapeutics, vaccine readiness, and other health products for COVID-19 | 20/11/2020     | Incident management and emergency operation officers, facility managers, pharmacists, biomedical engineers, IPC officers, planning officers, procurement officers, laboratory staff | • Tool developed to assess present and surge capacities for the treatment of COVID-19 in health facilities  
• Allows health facilities to assess availability and status of stockout of critical COVID-19 medicines, equipment and supplies on site and to identify areas that need further attention to enable the facility to respond effectively to the pandemic  
• Encompasses key components that are essential to managing COVID-19 in a hospital setting, including:  
  o Medicines for management of COVID-19  
  o Personal protective equipment  
  o Infection, prevention and control (IPC) supplies  
  o Diagnostic testing, imaging and patient monitoring devices and supplies  
  o Medical equipment for management of COVID-19  
  o COVID-19 vaccine readiness  
  o Beds and space capacity | Guidance       | COVID-19: Essential health services                                  |
| Maintaining surveillance of influenza and monitoring SARS-CoV-2 – adapting Global Influenza Surveillance and Response System (GISRS) and sentinel systems during the COVID-19 pandemic | 19/11/2020     | Public health professionals involved in disease and laboratory surveillance at the national level | • Extending objectives of influenza sentinel surveillance to COVID-19  
• Rapid situation assessment of the status of the sentinel surveillance system  
• Addressing disruptions in influenza sentinel surveillance systems  
• Practical considerations for extending influenza sentinel surveillance to COVID-19  
• Sampling strategy and sample size considerations  
• Laboratory considerations – sentinel surveillance specimens | Guidance       | COVID-19: Surveillance, case investigation and epidemiological protocols |
• The document will be used for:  
  o comparative evaluation of SARS-CoV-2 antigen tests  
  o evaluation of analytical sensitivity  
  o calibration of secondary references for SARS-CoV-2 antigen  
  o other regulatory and QA activities | Publication     | Access to Medicines and Health Products                              |
| WHO/BS.2020.2402 Collaborative Study for the Establishment of a WHO International Standard for SARS-CoV-2 RNA | 18/11/2020     | Laboratories and other stakeholders involved in SARS-CoV-2 diagnostics | • The intended use of the International Standard is for the calibration and control of nucleic acid amplification techniques which are considered the gold standard method for accurate diagnosis of infection  
• This document aims to assess the suitability of different SARS-CoV-2 preparations to serve as the International Standard for use in the harmonisation of COVID-19 NAT assays | Publication     | Access to Medicines and Health Products                              |
<table>
<thead>
<tr>
<th>Title</th>
<th>Latest version</th>
<th>Intended audience</th>
<th>Key themes</th>
<th>Document type</th>
<th>WHO website location (by topic)</th>
</tr>
</thead>
</table>
| WHO/BS.2020.2403 Establishment of the WHO International Standard and Reference Panel for anti-SARS-CoV-2 antibody | 18/11/2020     | Laboratories and other stakeholders involved in SARS-CoV-2 serological assays      | • The availability of an International Standard for antibodies would facilitate the standardisation of SARS-CoV-2 serological methods and allow for comparison and harmonisation of datasets across laboratories  
• This document aims to:  
  o assess the suitability of the candidate to serve as the International Standard for anti-SARS-CoV-2 antibody for use in the harmonisation of SARS-CoV-2 serology assays  
  o identify candidate COVID-19 antibody preparations for inclusion in a WHO Reference Panel for anti-SARS-CoV-2 antibodies                                                                                                                                                                                                 | Publication     | Access to Medicines and Health Products                                    |
| Guidance on developing a national deployment and vaccination planning for COVID-19 vaccines | 16/11/2020     | National governments, ministry of health                                           | • Provides a framework to support countries in:  
  o developing and updating their national deployment and vaccination plan for COVID-19 vaccines  
  o designing strategies for the deployment, implementation and monitoring of the COVID-19 vaccine in country  
  o ensuring the plan and related financing is well aligned to other national COVID-19 recovery and response and support plans, and implementation is fully integrated into national governance mechanisms.                                                                                                                                               | Guidance        | COVID-19: Critical preparedness, readiness and response                     |
| COVID-19 and Influenza                                               | 13/11/2020     | General public                                                                     | • Update on current global situation  
• Readiness for influenza during the COVID-19 pandemic  
  o Plan, prevent, care, test and monitor, communicate  
• WHO resources on influenza during COVID-19  
• How to protect ourselves and others                                                                                                                                                                                                                                                                                                                      | Powerpoint presentation | EPI-WIN updates – Update 41                                                  |
| Technical specifications of personal protective equipment for COVID-19 | 13/11/2020     | Procurement agencies, occupational health departments, infection prevention and control departments, health facility administrators, biomedical and materials engineering, PPE manufacturers and public health authorities (national and facility level) | • Provides guidance on the quality, performance characteristics and related standards of PPE to be used in the context of COVID-19  
  o Includes surgical masks, non-surgical masks, gloves, googles, face shields, gowns and N95 masks                                                                                                                                                                                                                                               | Guidance        | COVID-19: Infection prevention and control / WASH                             |
| Allocation mechanism for COVAX facility vaccines                     | 12/11/2020     | Governments, national health authorities                                           | • Explainer for countries based on commonly asked questions  
• Simple explanation of the guiding principles underpinning the allocation of COVAX vaccines  
• Allocation phases  
• Governance and prioritisation                                                                                                                                                                                                                                                                                                                        | Publication     | Publications                      |
<table>
<thead>
<tr>
<th>Title</th>
<th>Latest version</th>
<th>Intended audience</th>
<th>Key themes</th>
<th>Document type</th>
<th>WHO website location (by topic)</th>
</tr>
</thead>
</table>
| Readiness for influenza during the COVID-19 pandemic                  | 06/11/2020     | National authorities and decision makers  | • Provides a summary of information and considerations to ensure optimal management of influenza during the COVID-19 pandemic  
  • Addresses key issues such as:  
    o Potential co-circulation of influenza and SARS-CoV-2  
    o Differentiation between influenza and COVID-19 in patients  
    o Planning influenza prevention and control interventions | Policy brief    | COVID-19: Critical preparedness, response and readiness                                      |
| Considerations for implementing and adjusting public health and social measures in the context of COVID-19 | 04/11/2020     | National authorities and decision makers  | • Provides an updated transmission classification, sub-dividing “community transmission” into four sub-categories, from low to very high incidence  
  • Associated annex provides revised indicators and thresholds for determining the transmission classification, as well as the current health system capacity  
  • Provides a situational assessment matrix, which takes into consideration the transmission classification and the health system response capacity to arrive at an overall Situational Level  
  • Provides guidance about the public health and social measures to implement or adjust at each situational level | Guidance        | COVID-19: Critical preparedness, response and readiness                                      |
| Critical preparedness, readiness and response actions for COVID-19    | 04/11/2020     | Governments                                | • Defines four transmission scenarios:  
  o no cases  
  o sporadic cases  
  o clusters of cases  
  o community transmission  
  • Provides recommendations for each transmission scenario for critical preparedness, readiness and response actions  
  • Measures to reduce COVID-19 transmission and economic, public and social impacts | Guidance        | COVID-19: Critical preparedness, response and readiness                                      |
| Overview of the COVID-19 pandemic                                     | 04/11/2020     | General public                             | • The latest on the COVID-19 global situation and how the pandemic spread  
  o Phase 1: an unknown virus emerges  
  o Phase 2: a pandemic unfolds  
  o Phase 3: the pandemic accelerates  
  o Phase 4: where we are now  
  o What’s next  
  o How to protect ourselves and others  
  o WHO guidance on COVID-19 | Powerpoint presentation | EPI-WIN updates – Update 40                                                                 |
<table>
<thead>
<tr>
<th>Title</th>
<th>Latest version</th>
<th>Intended audience</th>
<th>Key themes</th>
<th>Document type</th>
<th>WHO website location (by topic)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Harmonized health service capacity assessments in the context of the COVID-19 pandemic</td>
<td>02/11/2020</td>
<td>National health authorities, health care facilities</td>
<td>• Suite of modules which is designed to meet country needs throughout the different phases of COVID-19 preparedness, response and recovery&lt;br&gt;• Aligned and consistent with all published WHO guidance on COVID-19&lt;br&gt;• Supports rapid and accurate assessments of the current, surge and future capacities of health facilities, to ensure they are prepared for and responsive to COVID-19 while maintaining the delivery of essential health services throughout all phases of the pandemic.&lt;br&gt;• Consists of two sets of modules:&lt;br&gt;  o Hospital readiness and case management capacity for COVID-19&lt;br&gt;  o Continuity of essential health services in the context of the COVID-19 pandemic</td>
<td>Guidance</td>
<td>COVID-19: Essential health services</td>
</tr>
<tr>
<td>Prevention, identification and management of health worker infection in the context of COVID-19</td>
<td>30/10/2020</td>
<td>Occupational health departments, infection prevention/control departments, health facility administrators and public health authorities</td>
<td>• Provides guidance on the prevention, identification and management of health worker infection in the context of COVID-19&lt;br&gt;• Key principles for preventing infections in health workers&lt;br&gt;• Early detection of SARS-CoV-2 infections in health workers to prevent further transmission&lt;br&gt;• Managing health worker exposures, infections and safe return to work&lt;br&gt;• Monitoring, studying and reporting health worker infections</td>
<td>Guidance</td>
<td>COVID-19: Essential health services</td>
</tr>
<tr>
<td>Roadmap for evaluation of AstraZeneca AZD1222 Vaccine against COVID-19</td>
<td>30/10/2020</td>
<td>Regulatory authorities</td>
<td>• The candidate vaccine AZD1222, developed by AstraZeneca (AZ) and the University of Oxford is a recombinant replication defective chimpanzee adenovirus expressing the SARS-CoV-2 S surface glycoprotein&lt;br&gt;• WHO agreed that a roadmap would be developed to outline the steps to follow for the submission and assessment for AZD1222 for Emergency Use Listing (EUL) / Prequalification (PQ) as well as a proposed pathway for the collaboration between WHO and the NRA of record&lt;br&gt;• This document provides an overview of the process to ensure expedited access to this vaccine.&lt;br&gt;• This roadmap is to service as a model for subsequent product specific vaccine evaluations</td>
<td>Roadmap</td>
<td>COVID-19: Laboratory and diagnosis</td>
</tr>
<tr>
<td>What we know about COVID-19 transmission in schools</td>
<td>23/10/2020</td>
<td>General public</td>
<td>• Children and COVID-19&lt;br&gt;• Risk of outbreaks when community transmission is high&lt;br&gt;• Implications for school public health policy&lt;br&gt;• How to support schools to stay safe</td>
<td>Powerpoint presentation</td>
<td>EPI-WIN updates – Update 39</td>
</tr>
<tr>
<td>Title</td>
<td>Latest version</td>
<td>Intended audience</td>
<td>Key themes</td>
<td>Document type</td>
<td>WHO website location (by topic)</td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>----------------</td>
<td>----------------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>---------------</td>
<td>--------------------------------</td>
</tr>
</tbody>
</table>
| Laboratory assessment tool for laboratories implementing SARS-CoV-2 testing | 23/10/2020     | National health authorities, multilateral agencies, Non-Governmental Organisations (NGOs) and laboratory managers | • Excel spreadsheet designed to assess capacities of existing laboratories which have implemented or aim to implement SARS-CoV-2 testing.  
• Addresses core capacities of a laboratory and specificities related to SARS-CoV-2 testing.  
• Focused and shorter version of existing complete laboratory assessment tool found here. | Tool          | COVID-19: Clinical preparedness, readiness and response |
| Assessment tool for laboratories implementing SARS-CoV-2 testing: Interim Guidance | 23/10/2020     | National health authorities, multilateral agencies, Non-Governmental Organisations (NGOs) and laboratory managers | • Tool is designed to assess the capacity of laboratories that have implemented or intend to implement testing for SARS-CoV-2  
• Enables rapid identification of strengths and weaknesses of a laboratory | User guide    | COVID-19: Clinical preparedness, readiness and response |
| Considerations in the investigation of cases and clusters of COVID-19 | 22/10/2020     | Local, regional or national health authorities                                    | • Offers guidance for rapid investigation of suspected COVID-19 cases and clusters | Guidance      | COVID-19: Surveillance, case investigation and epidemiological protocols |
| Frequently asked questions on regulation of COVID-19 vaccines         | 22/10/2020     | Governments, national health authorities, other stakeholders                      | • FAQ developed by COVAX Regulatory Advisory Group (RAG) to support COVID-19 vaccine developers.  
• Contains information and feedback regarding:  
  o Manufacturing  
  o Quality Control  
  o Stability  
  o Labelling  
  o Shelf-life/Expiry Date  
  o Clinical Vaccine Safety | Guidance      | Regulation and Prequalification, Regulation and safety |
• Designed to assess infection prevention and control capacities to respond to COVID-19 in health facilities. | Guidance      | COVID-19: Essential health services |
| Ensuring a safe environment for patients and staff in COVID-19 health-care facilities | 20/10/2020     | Health-care facilities                                                            | • Module from the suite of health service capacity assessments in the context of the COVID-19 pandemic.  
• Designed to assess the structural capacities of hospitals to allow safe COVID-19 case management, maintain the delivery of essential services and enable surge capacity planning. | Guidance      | COVID-19: Essential health services |
<table>
<thead>
<tr>
<th>Title</th>
<th>Latest version</th>
<th>Intended audience</th>
<th>Key themes</th>
<th>Document type</th>
<th>WHO website location (by topic)</th>
</tr>
</thead>
</table>
• A roadmap for planning which describes priority uses of COVID-19 vaccine based on various scenarios use.  
• Allocations, prioritization and recommendations of priority uses of COVID-19 vaccines based on:  
  o Group sizes  
  o Gender considerations  
  o Pregnant women  
  o Children  
  o Comorbidities | Guidance       | Immunization, Vaccines and Biologicals, Strategic Advisory Group of Experts on Immunization |
| What we know about COVID-19 vaccine development                       | 06/10/2020     | General public                                                                     | • Overview of current global situation  
• General information about vaccines:  
  o why we use them  
  o how they work  
  o delivery methods  
  o immunogens used  
  o mechanisms of action  
  o steps in vaccine development  
• COVID-19 vaccine development  
• Current candidates in Phase III trials  
• WHO Solidarity vaccine trial  
• COVID-19 vaccine development resources  
• WHO video resources on COVID-19 | Powerpoint presentation | EPI-WIN updates – Update 37                                                        |
| COVID-19 Supply Portal glossary                                      | 30/09/2020     | Governments, national health authorities, other stakeholders                      | • Definition of terms used in the WHO COVID-19 Supply Portal | Glossary       | Health Emergencies Preparedness and Response                                                                                                         |
| Diagnostic testing for SARS-CoV-2                                    | 11/09/2020     | Laboratories and other stakeholders involved in diagnostics                        | • Guidance to laboratories and other stakeholders involved in diagnostics  
• Includes relevant background information and clinical diagnostic algorithm  
• Updated with new findings from literature and best practices  
• Main considerations include:  
  o Specimen collection, shipment and storage  
  o Biosafety practices in the laboratory  
  o Testing for SARS-CoV-2  
  o Reporting of cases and test results | Guidance       | COVID-19: Laboratory and diagnosis                                                 |
<table>
<thead>
<tr>
<th>Title</th>
<th>Latest version</th>
<th>Intended audience</th>
<th>Key themes</th>
<th>Document type</th>
<th>WHO website location (by topic)</th>
</tr>
</thead>
</table>
| Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunassays | 11/09/2020     | National health authorities, laboratories and other stakeholders involved in diagnostics | • Advice on the role of antigen-detecting rapid diagnostic tests (Ag-RDT) in COVID-19 detection  
  o This new RDT technology is simpler and faster to perform and gives results in <30 minutes  
  o Ag-RDTs are substantially less sensitive than NAT  
  o Despite these limitations, Ag-RDTs could play a significant role in patient management, public health decision making and surveillance of COVID-19 | Guidance      | COVID-19: Laboratory and diagnosis                                            |
| What we know about long-term effects of COVID-19                      | 09/09/2020     | General public                                                                   | • Current global situation  
  • Long-term effects of COVID-19  
  • Monitoring social media  
  • WHO guidance and resources  
  • Upcoming events                                                                 | Powerpoint presentation | EPI-WIN updates: Update 36                                                      |
| Corticosteroids for COVID-19                                         | 02/09/2020     | Clinicians and health care decision makers                                       | • Role of systemic corticosteroids in the treatment of patients with COVID-19  
  • Recommendations:  
    o Use of systemic corticosteroids in treatment of patients with severe and critical COVID-19  
    o Do not use corticosteroids in the treatment of patients with non-severe COVID-19  
  • Outlines current evidence and clarifies the understanding for each of the recommendations | Guidance      | COVID-19: Clinical care                                                        |
  • 105 countries responded, with 90% reporting some disruption to essential health services  
  • Urgent blood transfusion services were partially disrupted in 19% of responding countries, and severely disrupted in 4% of responding countries | Report         | COVID-19: Essential health services                                             |
| Advice on the use of masks for children in the community in the context of COVID-19 | 21/08/2020     | Decision makers, public and child health professionals                           | • Advice on use of masks in children during the COVID-19 pandemic  
  • Specific considerations for use of non-medical (fabric) masks for children  
<table>
<thead>
<tr>
<th>Title</th>
<th>Latest version</th>
<th>Intended audience</th>
<th>Key themes</th>
<th>Document type</th>
<th>WHO website location (by topic)</th>
</tr>
</thead>
</table>
| Transmission of SARS-CoV-2: implications for infection prevention precautions | 09/07/2020     | Governments, national health authorities      | • Overview of modes of transmission of SARS-CoV-2  
  o contact and droplet transmission  
  o airborne transmission  
  o fomite transmission  
  o other modes  
  • What is known about when infected people transmit the virus  
  o droplets and close contact  
  o asymptomatic transmission  
  o remaining questions related to transmission  
  • Implications for infection prevention and control precautions within and outside health facilities  
  o limiting close contact  
  o identifying, testing, isolating  
  o use of masks | Scientific brief | COVID-19: Infection prevention and control / WASH |
| Asks' to the private sector in the response to COVID-19               | 11/06/2020     | Private sector businesses                      | • Health measures for business to protect against COVID-19  
  o protect stakeholders  
  o protect business  
  o essential supplies  
  o financial support | Publication    | COVID-19                                       |
| Maintaining essential health services: operational guidance for the COVID-19 context | 01/06/2020     | Decision makers and managers at national and subnational levels | • Operational strategies for maintaining essential health services  
  o Basic principles and practical recommendations that support decision-making to ensure continuity of essential health services, highlighting key actions that countries should consider  
  • Life course and disease considerations  
  o Specific adaptations and considerations for life course and disease programmes in the context of COVID-19 | Guidance       | COVID-19: Essential health services |
| Overview of public health and social measures in the context of COVID-19 | 18/05/2020     | National and local health authorities, other decision makers | • Public health and social measures to stop individual chains of transmission and prevent outbreaks  
  • Applying public health and social measures according to level of disease transmission  
  • Balancing the benefit and risks of public health and social measures  
  • Tables containing information on:  
    o Selected public health and social measures for consideration in the context of COVID-19  
    o Considerations for successful implementation of public health and social measures in the context of COVID-19  
    o Sample strategies and policies for limiting secondary effects of implementing public health and social measures | Guidance       | COVID-19: Critical preparedness, readiness and response |
<table>
<thead>
<tr>
<th>Title</th>
<th>Latest version</th>
<th>Intended audience</th>
<th>Key themes</th>
<th>Document type</th>
<th>WHO website location (by topic)</th>
</tr>
</thead>
</table>
| Cleaning and disinfection of environmental surfaces in the context of COVID-19 | 16/05/2020     | Health care professionals, public health professionals and health authorities                                | • Advice on cleaning and disinfection of environmental surfaces in the context of COVID-19  
  o Principles of cleaning and disinfection  
  o Training in health-care settings  
  o Cleaning and disinfection techniques and supplies  
  o Products for environmental cleaning and disinfection  
  o Spraying disinfectants and other no-touch methods  
  o Health care settings environment  
  o Non-health care settings environment  
  o Personal safety when preparing and using disinfectants | Guidance      | COVID-19: Infection prevention and control / WASH                                                         |
| Considerations for public health and social measures in the workplace in the context of COVID-19 | 10/05/2020     | Those involved in developing policies and SOPs to prevent transmission of COVID-19 in the workplace – employers, workers, labour unions, business associations, local public health and labour authorities, OHS practitioners | • General guidance for preventing the transmission of COVID-19 in the non-healthcare workplace  
  • Workplace risk assessment considerations, specific measures for medium risk and high risk workplaces/jobs  
  • Preventative measures including hand hygiene, respiratory hygiene, physical distancing, reduced work-related travel, regular cleaning/disinfection, risk communication, training and education, management of people with COVID-19 or their contacts  
  • Rights, duties and responsibilities of workers and employers | Annex         | COVID-19: Critical preparedness, readiness and response                                                   |
| Recommendations to Member States to improve hand hygiene practices to help prevent the transmission of the COVID-19 virus | 01/04/2020     | All countries, particularly areas without ready access to hand hygiene locations                          | • Recommendations for improving hand hygiene practices to help prevent COVID-19 transmission by:  
  o Providing universal access to public hand hygiene stations  
  o Making their use obligatory on entering and leaving public or private commercial buildings and public transport  
  o Improving access to hand hygiene facilities and practices in health care facilities | Guidance      | COVID-19: Essential health services                                                                       |
<table>
<thead>
<tr>
<th>Title</th>
<th>Latest version</th>
<th>Intended audience</th>
<th>Key themes</th>
<th>Document type</th>
<th>WHO website location (by topic)</th>
</tr>
</thead>
</table>
| Getting your workplace ready for COVID-19: How COVID-19 spreads     | 19/03/2020     | Employers, workers          | • Advice on preventing the spread of COVID-19 in the workplace  
  o cleaning and hygiene  
  o promotion of regular hand-washing  
  o promotion of good respiratory hygiene  
  o consulting national travel advice  
  o staying at home when symptomatic  
• Managing COVID-19 risks during meetings and events  
• Considerations for work-related travel  
• Getting the workplace ready in case of community transmission  
  o develop a plan in case a staff member becomes ill with COVID-19  
  o promotion of teleworking  
  o develop a contingency and business continuity plan for an outbreak in the community where the business operations | Publication    | COVID-19: Schools, businesses and institutions |
| Risk communication and community engagement readiness and response to COVID-19 | 19/03/2020     | Governments, national health authorities | • Checklists for risk communication and community engagement readiness and initial responses to COVID-19 outbreak  
  o risk communication systems  
  o internal and partner coordination  
  o public communication  
  o community engagement  
  o addressing uncertainty and perceptions and managing misinformation  
  o capacity building  
• Global collaboration in monitoring for infectious threats to the blood supply  
• Accurate and reliable information about a threat  
• Understanding the implications of the threat  
• Possible actions to respond to a threat  
• Risk assessment of the threat and options  
• Communication  
• Haemovigilance  
• Resolution of an outbreak  
• Non-blood donors and donations  
• Responsibilities of WHO and national blood services  
• Checklist for dealing with a disease outbreak | Guidance       | COVID-19: Risk communication and community engagement |
| Protecting the blood supply during infectious disease outbreaks: guidance for national blood services | 02/01/2019     | National blood services     | • Assists blood services in the development of national plans to respond to any emerging infectious threats to the sufficiency and safety of the blood supply  
  o Global collaboration in monitoring for infectious threats to the blood supply  
  o Accurate and reliable information about a threat  
  o Understanding the implications of the threat  
  o Possible actions to respond to a threat  
  o Risk assessment of the threat and options  
  o Communication  
  o Haemovigilance  
  o Resolution of an outbreak  
  o Non-blood donors and donations  
  o Responsibilities of WHO and national blood services  
  o Checklist for dealing with a disease outbreak | Publication    | Blood products |
<table>
<thead>
<tr>
<th>Title</th>
<th>Latest version</th>
<th>Intended audience</th>
<th>Key themes</th>
<th>Document type</th>
<th>WHO website location (by topic)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Use of Convalescent Plasma, Serum or Immune Globulin Concentrates as an Element in Response to an Emerging Virus</td>
<td>14/09/2017</td>
<td>National blood services, regulatory authorities</td>
<td>• Rationale for consideration of use of convalescent plasma or serum</td>
<td>Position Paper</td>
<td>WHO Blood Regulators Network</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>o collection and use of convalescent plasma or serum</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>o regulatory considerations</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>o criteria for patient treatment</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>o outcome monitoring</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>o feasibility of large scale production including</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>manufacture of purified immunoglobulins</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>